Limb-girdle muscular dystrophy type 2A (LGMD2A), also known as Erb's dystrophy, is a hereditary disease characterized by progressive muscle wasting and weakness that begins in childhood or adolescence. The underlying pathology in this disease is genetically determined degeneration of myofibrils, which causes a gradual loss of muscle mass and dysfunction. In LGMD2A, distal and proximal muscles are particularly susceptible, which makes it difficult to perform daily functions and worsens the quality of life of patients. The disease is associated with dysfunction of the dystrophin-like protein, which causes dysfunction in muscle tissue. The clinical picture can vary from mild to severe, often with manifestations of statics, twitching of the limbs, as well as increased fatigue.
History of the disease and interesting historical facts
The history of the study of limb-girdle muscular dystrophy goes back to the end of the 19th century, when doctors began to describe the clinical manifestations of diseases similar in nature. The first cases documented in medical literature were identified in Great Britain and Europe. Around 1891, the German neurologist V. Njogti first described a condition similar to modern LMMD, which marked the beginning of a systematic study of this disease. Interestingly, among celebrities suffering from this form of dystrophy, one can single out such personalities as the English singer and composer Elton John, which emphasizes not only the medical, but also the social significance of this disease.
Epidemiology
The epidemiology of LMD2A shows that the prevalence of the disease varies by region, but on average it occurs in 1 in 20,000 to 30,000 live births. This means that the disease occurs in 0.3–0.5 cases per 1,000 people. There is a genetic predisposition to the disease among populations, as evidenced by the higher incidence in families with a history of muscular dystrophy. To date, more than 1,000 cases of limb-girdle muscular dystrophy have been reported worldwide, highlighting the importance of genetic testing and mandatory case histories.
Genetic predisposition to this disease
LMMD2A is caused by mutations in genes responsible for the synthesis of muscle proteins that are critical for the normal functioning of muscle cells. In particular, the disease is associated with mutations in the DYSF gene, which encodes the protein dysphasin, which affects muscle tissue regeneration and integrity. Existing studies confirm that patients with limb-girdle muscular dystrophy also have other associated mutations that can affect the course of the disease and its clinical manifestations. Genetic testing for the presence of certain mutations can significantly help in diagnosing and predicting the progression of the disease.
Risk factors for the development of this disease
The main risk factor for developing CMMD2A is a hereditary predisposition. Other factors that may contribute to the progression of the disease include:
- Male gender, since the disease is more common in men due to the recessive type of inheritance.
- Predominance of cases in families with previous records of muscular dystrophies.
- Consanguinity between parents, which increases the likelihood of passing on gene mutations.
- Environmental factors, such as the use of certain chemicals, that can affect the health of the nervous system.
Diagnosis of this disease
Diagnosis of limb-girdle muscular dystrophy is based on a comprehensive approach, including clinical studies, laboratory tests and instrumental methods.
- The main symptoms include progressive muscle weakness, decreased physical endurance, walking difficulties and difficulty performing daily activities.
- Laboratory tests typically show elevated levels of creatine phosphokinase (CPK) in the blood, indicating muscle cell damage.
- Radiological examinations such as MRI can assess the condition of muscle tissue and identify atrophy.
- Additional diagnostic tests include electromyography (EMG) for temporal analysis of muscle contraction.
- Differential diagnosis must be carried out with other types of myopathies and dystrophies.
Treatment
Treatment of limb-girdle muscular dystrophy should primarily be comprehensive and include pharmacological, surgical and rehabilitation measures. Common approaches include:
- Pharmacological treatment is aimed at muscle health and improving functional capabilities. Anti-inflammatory drugs, steroids, and other medications are used.
- Surgical treatment may include scoliosis correction and other surgeries aimed at improving the structure of the musculoskeletal system.
- Physiotherapy sessions and specialized rehabilitation programs aimed at maintaining muscle tone and improving quality of life.
- Innovative methods such as gene therapy and the use of cell technologies are also being explored as potential treatments for the disease.
List of medications used to treat this disease
Medicines used to treat CMMD2A include:
- Dexamethasone
- Prednisolone
- Avastin (Bevacizumab)
- Muscle relaxants
- Preparations containing low molecular weight anticoagulants to reduce stiffness.
Disease monitoring
Monitoring the course of CPMD2A requires regular assessment of patients' condition, including:
- Control stages for periodic assessment of muscle function and the condition of the musculoskeletal system.
- The prognosis of the disease varies, as a rule, severe forms progress more quickly and can worsen the quality of life. Mild forms have a better prognosis.
- Complications associated with the disease include respiratory problems, cardiovascular disorders, and the development of contractures.
Age-related features of the disease
CMMD2A can manifest at different ages, and clinical manifestations can vary:
- In children, the disease usually begins at the age of 5-15 years with manifestations of weakness of the distal muscles.
- In young and adulthood, symptoms may be more pronounced, allowing the disease to be diagnosed at an early stage.
- In older people, disease progression may be slower, but serious complications associated with other age-related diseases are possible.
Questions and Answers
- What are the main symptoms of CMMD2A? The main symptoms include progressive muscle weakness, difficulty walking, falls, fatigue and limb deformities.
- What is the genetic predisposition to the disease? The disease is most often inherited from parents to children, especially in men, since the genetic mutation is often recessive.
- What is the treatment for CMMD2A? Treatment includes drug therapy to control inflammation, physical therapy and surgery.
- How do doctors conduct examinations? Patients should undergo regular examinations using laboratory and instrumental studies to monitor muscle condition and identify possible complications.
- What is the prognosis for patients with CMMD2A? The prognosis varies depending on the severity of the disease, with mild forms having a better outcome, while severe cases can lead to loss of mobility.
Advice from Dr. Oleg Korzhikov
With proper treatment and recommendations, the quality of life of patients with limb-girdle muscular dystrophy can be greatly improved. It is important to undergo regular check-ups and not ignore symptoms in order to respond to changes in a timely manner. Patients should maintain an active lifestyle, including exercises that are appropriate for them, and follow a diet that supports muscle health. The main thing is not to be embarrassed to ask questions of your doctor and to be open to rehabilitation methods that can help improve your condition.
